Global organization gener8tor, along with Downtown Launchpad, started its ninth gBETA Houston cohort last month. Photo via Getty Images

For the ninth time, gBETA is incubating five early-stage Houston startups providing innovative solutions across skincare, human resources, and more.

Global organization gener8tor, along with Downtown Launchpad, started its ninth gBETA Houston cohort last month. The free seven-week, no-equity accelerator program selected five Houston-based founders to provide helpful programming, support, and connections to mentors, customers, corporate partners, and investors.

"We're thrilled to continue fostering innovation in Houston and are thankful for our collaboration with Downtown Launchpad as we launch the ninth cohort of gBETA Houston,” says Vanessa Huerta, vice president of gBETA at gener8tor, in a statement.

The program has accelerated 40 Houston companies since its launch in Houston a few years ago. The companies have gone on to raise over $8.6 million in funding and created more than 70 jobs.

“With each new cohort, we witness the power of innovation unleashed,” Muriel Foster, gBETA Houston director, says in the release. “The Spring 2024 gBETA Houston cohort embodies the spirit of relentless creativity and boundless ambition.”

The gBETA Houston Spring 2024 Cohort includes:

  • Cosnetix is innovating within personalized skincare, leveraging genetic and microbial skin profiling to offer users custom skincare product recommendations. The platform has been developed through over 100 customer discovery interviews and is headed for beta-testing.
  • Kannect has created an innovative community engagement platform — already used by 20 organizations — to streamline communication, foster collaboration, and enhance member engagement. The tools can be used by nonprofits, associations, religious institutions, and beyond as a digital dashboard to manage memberships, organize events, and facilitate meaningful interactions.
  • Targeting college grads and career pivoters, No Experience Jobs helps users find entry-level jobs that don’t require experience. In its first three months of launching, NoExperienceJobs.io received more than 72,000 unique monthly visitors, gained over 1,300 newsletter subscribers, generated more than 700,000 social media engagements, and is already revenue-generating.
  • The Roo App partners with bars and restaurants to connect designating drivers to those who need designated driver services. The company is currently operation on a web-based platform with over 1,500 current visitors, but plans to launch the mobile application later this year.
  • Yuyo.love is changing the fitness game by providing bilingual fitness classes ranging from yoga, pilates, dance, fitness, nutrition, and meditation. The company's hybrid classes have over 150 participants per class and plans to launch the platform this quarter.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.